|
gptkbp:instanceOf
|
gptkb:drug
muscle relaxant
|
|
gptkbp:approvedBy
|
1974
|
|
gptkbp:ATCCode
|
M03CA01
|
|
gptkbp:brand
|
Dantrium
Revonto
Ryanodex
|
|
gptkbp:CASNumber
|
7261-97-4
|
|
gptkbp:category
|
hydantoin derivative
skeletal muscle relaxant
|
|
gptkbp:chemicalFormula
|
C14H10N4O5
|
|
gptkbp:contraindication
|
active liver disease
|
|
gptkbp:developedBy
|
Dr. Keith Ellis
|
|
gptkbp:eliminationHalfLife
|
8.7 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dantrolene
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits calcium release from sarcoplasmic reticulum
|
|
gptkbp:MedlinePlusID
|
a682043
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
314.26 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
2955
DB01219
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
dizziness
muscle weakness
hepatotoxicity
drowsiness
|
|
gptkbp:UNII
|
F0V85T346W
|
|
gptkbp:usedFor
|
spasticity
malignant hyperthermia
neuroleptic malignant syndrome
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Neuroleptic_Malignant_Syndrome
|
|
gptkbp:bfsLayer
|
7
|